InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
2
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+12.4%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Buten Matthew. Director active across 2 companies, notably Biohaven Pharmaceutical Holding Co Ltd.. Cumulatively, 7 disclosures have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €2m. History available since 31 December 2021. The latest transaction was disclosed on 5 January 2026 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Buten Matthew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
4,250 shares0Common SharesSEC:0001898799-26-000002:0
4,250 shares0Common SharesSEC:0001935979-25-000003:0
22,727 shares@ US$22.0023.9% of flowCommon SharesSEC:0001562180-23-007229:0
Canonical exit: 3 Jan 2024 (T+90)
142,857 shares@ US$10.5076.1% of flowCommon SharesSEC:0001562180-22-007333:0
Canonical exit: 23 Jan 2023 (T+90)
3,088 shares0Common SharesSEC:0001562180-22-007076:0
6,177 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006959:0
12,500 shares0Common SharesSEC:0001562180-22-000183:0
7 of 7 declarations
About Buten Matthew
Buten Matthew is a declarant associated with Biohaven Ltd. and Biohaven Pharmaceutical Holding Co Ltd., where he is Chief Financial Officer. Across 7 filings in total, the most recent sampled filings run from 2022-01-04 to 2025-01-07, with EUR 1979538 of buys and EUR 932952 of sells, and the most frequent transaction nature is Levée d'options.
